Is there a future for metabotyping in clinical laboratories?

“...most importantly, metabotyping determination is feasible with realistic workloads, workflows and costs. This new technique will precede most requests from MD, PharmD and PhD researchers followed by clinicians, who will rapidly understand the usefulness of a more global patient metabotyping than what is currently available.” Today, hospital laboratories perform various analyses that can be categorized by their two principal workflows, mainly defined by the analytical systems used and the delay for results reporting. The biomatrices are mainly plasma and to a lesser extent serum, urine and cerebrospinal fluid. The first workflow is a 24/7 support, uses large automated clinical chemistry...